ADC Therapeutics SANYSE:ADCT
- LAST PRICE3.4700
- TODAY'S CHANGE (%)-0.0700 (-1.9774%)
- Bid / Lots3.4600/ 1
- Ask / Lots3.4700/ 3
- Open / Previous Close3.5300 / 3.5400
- Day Range
- 52 Week Range
- Volume89,752
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ADCT |
|---|---|---|
| 09:32 ET | 2316 | 3.5296 |
| 09:34 ET | 400 | 3.5 |
| 09:36 ET | 1970 | 3.5 |
| 09:39 ET | 1716 | 3.49 |
| 09:41 ET | 10900 | 3.51 |
| 09:45 ET | 300 | 3.51 |
| 09:48 ET | 2657 | 3.48 |
| 09:56 ET | 500 | 3.48 |
| 09:57 ET | 200 | 3.48 |
| 09:59 ET | 200 | 3.48 |
| 10:01 ET | 100 | 3.5 |
| 10:03 ET | 850 | 3.5 |
| 10:06 ET | 200 | 3.5 |
| 10:08 ET | 2783 | 3.49 |
| 10:10 ET | 1496 | 3.48 |
| 10:12 ET | 1400 | 3.46 |
| 10:14 ET | 524 | 3.44 |
| 10:15 ET | 300 | 3.425 |
| 10:21 ET | 100 | 3.44 |
| 10:24 ET | 1200 | 3.41 |
| 10:28 ET | 4673 | 3.43 |
| 10:32 ET | 2700 | 3.44 |
| 10:33 ET | 1040 | 3.445 |
| 10:35 ET | 600 | 3.46 |
| 10:37 ET | 703 | 3.46 |
| 10:39 ET | 500 | 3.49 |
| 10:42 ET | 940 | 3.49 |
| 10:44 ET | 300 | 3.52 |
| 10:48 ET | 700 | 3.51 |
| 10:50 ET | 100 | 3.53 |
| 10:51 ET | 300 | 3.52 |
| 10:53 ET | 200 | 3.505 |
| 10:55 ET | 300 | 3.52 |
| 11:00 ET | 100 | 3.53 |
| 11:02 ET | 686 | 3.525 |
| 11:04 ET | 300 | 3.53 |
| 11:08 ET | 2180 | 3.525 |
| 11:09 ET | 2057 | 3.5 |
| 11:11 ET | 100 | 3.49 |
| 11:13 ET | 525 | 3.49 |
| 11:18 ET | 400 | 3.46 |
| 11:24 ET | 386 | 3.49 |
| 11:36 ET | 300 | 3.48 |
| 11:38 ET | 100 | 3.48 |
| 11:40 ET | 1149 | 3.47 |
| 11:44 ET | 100 | 3.46 |
| 11:45 ET | 814 | 3.46 |
| 11:49 ET | 100 | 3.46 |
| 11:51 ET | 1200 | 3.46 |
| 11:56 ET | 300 | 3.46 |
| 11:58 ET | 852 | 3.45 |
| 12:05 ET | 300 | 3.45 |
| 12:18 ET | 1396 | 3.44 |
| 12:21 ET | 100 | 3.44 |
| 12:25 ET | 246 | 3.43 |
| 12:27 ET | 466 | 3.44 |
| 12:30 ET | 1269 | 3.43 |
| 12:32 ET | 3800 | 3.4 |
| 12:36 ET | 1946 | 3.42 |
| 12:38 ET | 200 | 3.42 |
| 12:39 ET | 300 | 3.42 |
| 12:41 ET | 200 | 3.42 |
| 12:43 ET | 200 | 3.42 |
| 12:45 ET | 100 | 3.43 |
| 12:48 ET | 100 | 3.43 |
| 12:50 ET | 100 | 3.42 |
| 12:52 ET | 400 | 3.42 |
| 12:54 ET | 300 | 3.42 |
| 12:56 ET | 440 | 3.43 |
| 12:59 ET | 400 | 3.42 |
| 01:01 ET | 3193 | 3.44 |
| 01:03 ET | 1351 | 3.47 |
| 01:06 ET | 1686 | 3.47 |
| 01:08 ET | 100 | 3.47 |
Jun 3, 2024
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan, from 4:05PM ET on Monday Jun 03, 2024 by Dow Jones
4:05PM ET on Monday Jun 03, 2024 by Dow Jones
May 30, 2024
DJ ADC Therapeutics Initiated at Overweight by Cantor Fitzgerald, from 9:06AM ET on Thursday May 30, 2024 by Dow Jones
9:06AM ET on Thursday May 30, 2024 by Dow JonesADC Therapeutics to Participate in the Jefferies Global Healthcare Conference, from 7:15AM ET on Thursday May 30, 2024 by Dow Jones
7:15AM ET on Thursday May 30, 2024 by Dow Jones
May 15, 2024
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ, from 7:15AM ET on Wednesday May 15, 2024 by Dow Jones
7:15AM ET on Wednesday May 15, 2024 by Dow Jones
May 9, 2024
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference, from 7:15AM ET on Thursday May 09, 2024 by Dow Jones
7:15AM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ADC Therapeutics SA | 329.9M | -1.3x | --- |
Poseida Therapeutics Inc | 289.9M | -2.3x | --- |
Codexis Inc | 238.5M | -3.9x | --- |
Adaptimmune Therapeutics PLC | 288.8M | -1.4x | --- |
Enanta Pharmaceuticals Inc | 264.1M | -2.0x | --- |
Fate Therapeutics Inc | 418.9M | -1.9x | --- |
Company Information
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Contact Information
- Headquarters
- Biopole, route de la Corniche 3BEPALINGES, Switzerland 1066
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Ron Squarer
- Chief Executive Officer, Director
- Ameet Mallik
- Chief Financial Officer
- Jose Carmona
- Chief Scientific Officer
- Patrick Van Berkel
- Chief Legal Officer
- Peter Graham
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $329.9M |
|---|---|
Revenue (TTM) | $68.6M |
Shares Outstanding | 96.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.62 |
EPS | $-2.77 |
Book Value | $-1.80 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 4.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -216.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
